Pharmacological modulation of ion channels and transporters

Cell Calcium

Volumn 35, Issue 6, 2004, Pages 575-582

  Ravens, Ursula ^b   Wettwer, Erich ^b   Hála, Ottá ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b NONE

Author keywords

Antiarrhythmic drugs; Cardiac myocytes; Inotropic drugs; Ion channels; Ion transporters

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 4 [3 (1 BENZHYDRYL 3 AZETIDINYLOXY) 2 HYDROXYPROPOXY] 1H INDOLE 2 CARBONITRILE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTIARRHYTHMIC AGENT; BDF 9196; CALCIUM ION; CARDIOVASCULAR AGENT; CARRIER PROTEIN; COTRIMOXAZOLE; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; DPI 201107; ERYTHROMYCIN; FLECAINIDE; IBUTILIDE; ION CHANNEL; LIDOCAINE; MIBEFRADIL; N [1 [4 (4 FLUOROPHENOXY)BUTYL] 4 PIPERIDINYL] N METHYL 2 BENZOTHIAZOLAMINE; NIFEDIPINE; POTASSIUM CHANNEL BLOCKING AGENT; PROCAINAMIDE; QUINIDINE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM ION; SODIUM PROTON EXCHANGE PROTEIN; SOTALOL; SPARFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CELL DAMAGE; CELL MEMBRANE POTENTIAL; CELL PROTECTION; DRUG INDICATION; DRUG TARGETING; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE POTENTIAL; HEART PROARRHYTHMIA; HUMAN; INOTROPISM; ION TRANSPORT; LIVER TOXICITY; MODULATION; NONHUMAN; PRIORITY JOURNAL; PROTON SODIUM EXCHANGE; REVIEW; SODIUM CALCIUM EXCHANGE; SODIUM CELL LEVEL;

EID: 2442532944     PISSN: 01434160     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceca.2004.01.011     Document Type: Article

References (100)

1. D.M. Bers, Excitation-Contraction Coupling and Cardiac Contractile Force, Kluwer Academic Publishers, Dordrecht, 2002.
2. S. Dhein, Gap junction channels in the cardiovascular system: pharmacological and physiological modulation, Trends Pharmacol. Sci. 19 (1998) 224-229.
3. R.C. Thomas, Electrogenic sodium pump in nerve and muscle cells, Physiol. Rev. 52 (1972) 563-594.
4. M.P. Blaustein, W.J. Lederer, Sodium/calcium exchange: its physiological implications, Physiol. Rev. 79 (1999) 763-854.
5. L. Fliegel, J.R.B. Dyck, Molecular biology of the cardiac sodium/hydrogen exchanger, Cardiovasc. Res. 29 (1995) 155-159.
6. 2+ overload in reperfused ischemic myocardium, Annu. Rev. Physiol. 52 (1990) 543-559.
7. C.H. Orchard, J.C. Kentish, Effects of changes of pH on the contractile function of cardiac muscle, Am. J. Physiol. 258 (1990) C967-C981.
8. D.M. Roden, R. Lazzara, M. Rosen, P.J. Schwartz, J. Towbin, M. Vincent, For the SADS foundation task force on LQTS, Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions, Circulation 94 (1996) 1996-2012.
9. E. Vaughan Williams, A classification of antiarrhythmic actions reassessed after a decade of new drugs, J. Clin. Pharmacol. 24 (1984) 129-147.
10. L.M. Hondeghem, B.G. Katzung, Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs, Annu. Rev. Pharmacol. Toxicol. 24 (1984) 387-423.
11. C.F. Starmer, A.O. Grant, H.C. Strauss, Mechanisms of use-dependent block of sodium channels in excitable membranes by local anesthetics, Biophys. J. 46 (1984) 15-27.
12. U. Ravens, Electromechanical studies on an Anemonia sulcata toxin in mammalian cardiac muscle, Naunyn-Schmiedeberg's Arch. Pharmacol. 296 (1976) 73-78.
13. P. Honerjäger, Cardioactive substances that prolong the open state of sodium channels, Rev. Physiol. Biochem. Pharmacol. 92 (1982) 1-74.
14. G. Isenberg, U. Ravens, The effects of the Anemonia sulcata toxin (ATX II) on membrane currents of isolated mammalian myocytes, J. Physiol. 357 (1984) 127-149.
15. D. Buggisch, G. Isenberg, U. Ravens, G. Scholtysik, The role of sodium channels in the effects of the cardiotonic compound DPI 201-106 on contractility and membrane potentials in isolated heart preparations, Eur. J. Pharmacol. 118 (1985) 303-311.
16. A. Hoey, S.M. Harrison, M.R. Boyett, U. Ravens, Effects of the Annemonia sulcata toxin (ATX II) on intracellular sodium and contractility in rat and guinea-pig myocardium, Pharmacol. Toxicol. 75 (1994a) 356-365.
17. A. Hoey, G.J. Amos, U. Ravens, Comparison of the action otential prolonging and positive inotropic activity of DPI 201-106 and BDF 9148 in human ventricular myocardium, J. Mol. Cell. Cardiol. 26 (1994) 985-994.
18. U. Ravens, G.J. Amos, T. Ehring, G. Heusch, BDF 9148 - a sodium channel modulator with positive inotropic action, Cardiovasc. Drug Rev. 13 (1995) 260-274.
19. +-channel modulating effect of the inotropic compound S(- BDF9196 in human myocardium, Naunyn-Schmiedeberg's Arch. Pharmacol. 359 (1999) 60-64.
20. + channel activators as positive inotropic agents for the treatment of chronic heart failure, Cardiovasc. Drugs Ther. 15 (2001) 379-386.
21. Y.K. Ju, D.A. Saint, P.M. Gage, Hypoxia increases persistent sodium current in rat ventricular myocytes, J. Physiol. 497 (1996) 337-347.
22. P. Koch, B. Wilffert, T. Peters, R56865: a new antiischemic principle, Cardiovasc. Drug Rev. 8 (1990) 238-254.
23. + current by R56865 in single cardiac Purkinje cells, Eur. J. Pharmacol. 203 (1991) 371-378.
24. D. Wilhelm, H. Himmel, U. Ravens, T. Peters, Characterization of the interaction of R56865 with cardiac Na- and L-type Ca channels, Br. J. Pharmacol. 104 (1991) 483-489.
25. + channels: slip mode conductance, Science 279 (1998) 1027-1033.
26. 2+ currents in human atrial cells, Receptors Channels 3 (1995) 71-81.
27. R. Aggarwal, S.R. Shorofsky, L. Goldman, C.W. Balke, Tetrodotoxin-blockable calcium current in rat ventricular myocytes: a third type of cardiac cell sodium current, J. Physiol. 505 (1997) 353-393.
28. + channels in guinea pig ventricular myocytes, Am. J. Physiol. 273 (1997) H128-H137.
29. 2+ currents coexist in guinea pig ventricular myocytes and are both blocked by mibefradil, Circ. Res. 86 (2000) 628-635.
30. H.B. Nuss, E. Marban, C.W. Balke, L. Goldman, R. Aggarwal, S.R. Shorofsky, Whether 'slip mode conductance' occurs, Science 284 (1999) 711.
31. F. Hofmann, L. Lacinova, N. Klugbauer, Voltage-dependent calcium channels: from structure to function, Rev. Physiol. Biochem. Pharmacol. 139 (1999) 33-87.
32. P.J. Bernink, G. Prager, A. Schelling, I. Kobrin, Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group, Hypertension 3 (1996) 426-432.
33. S. Braun, E.E. van der Wall, H. Emanuelsson, I. Kobrin, Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group, J. Am. Coll. Cardiol. 27 (1996) 317-322.
34. T. Prueksaritanont, B. Ma, C. Tang, Y. Meng, C. Assang, P. Lu, P.J. Reider, J.H. Lin, T.A. Baillie, Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations, Br. J. Clin. Pharmacol. 47 (1999) 291-298.
35. T.F. McDonald, S. Pelzer, W. Trautwein, D.J. Pelzer, Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells, Physiol. Rev. 74 (1994) 365-507.
36. M. Kobayashi, R. Ochi, Y. Ohizumi, Maitotoxin-activated single calcium channels in guinea-pig cardiac cells, Br. J. Pharmacol. 92 (1987) 665-671.
37. 2+ channels, Nature 303 (1983) 535-537.
38. T. Beyer, N. Gansohr, P. Gjörstrup, U. Ravens, The effects of the cardiotonic dihydropyridine derivatives Bay k 8644 and H160/51 on post-rest adaptation of guinea-pig papillary muscles, Naunyn-Schmiedeberg's Arch. Pharmacol. 334 (1986) 488-495.
39. S. Viskin, Long QT syndromes and torsade de pointes, Lancet 354 (1999) 1625-1633.
40. + channel diversity in the mammalian myocardium, J. Physiol. 525 (2000) 285-298.
41. M. Näbauer, D.J. Beuckelmann, P. Uberfuhr, G. Steinbeck, Regional differences in current density and rate-dependent properties of the transient outward current in subepicardial and subendocardial myocytes of human left ventricle, Circulation 93 (1996) 168-177.
42. S. Kääb, J. Dixon, J. Duc, D. Ashen, M. Näbauer, D.J. Beuckelmann, G. Steinbeck, D. McKinnon, G.F. Tomaselli, Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density, Circulation 98 (1998) 1383-1393.
43. to-Expression? Z. Kardiol. 92 (2003) I/82.
44. E. Wettwer, G.J. Amos, H. Posival, U. Ravens, Transient outward current in human ventricular myocytes of subepicardial and subendocardial origin, Circ. Res. 75 (1994) 473-482.
45. H.B. Nuss, D.C. Johns, S. Kääb, G.F. Tomaselli, D. Kass, J.H. Lawrence, E. Marban, Reversal of potassium channel deficiency in cells from failing hearts by adenoviral gene transfer: a prototype for gene therapy for disorders of cardiac excitability and contractility, Gene Ther. 3 (1996) 900-912.
46. G.J. Amos, E. Wettwer, F. Metzger, Q. Li, H.M. Himmel, U. Ravens, Differences between outward currents of human atrial and subepicardial ventricular myocytes, J. Physiol. 491 (1996) 31-50.
47. Kur on the action potential shape in isolated human atrial preparations and computer simulations, Int. J. Biomagnetism 5 (2003) 265-266.
48. to-blocker (AVE0118) in the goat, Circulation 106 (2002) II-155.
49. +-Kanalblockers AVE0118, Z. Kardiol. 92 (Suppl 1) (2003) I/351-I/352.
50. + current. Differential sensitivity to block by class III antiarrhythmic agents, J. Gen. Physiol. 96 (1990) 195-215.
51. + channel. Open-channel block by methanesulfonanilides, Circ. Res. 78 (1996) 499-503.
52. L.M. Hondeghem, D. Snyders, Class III antiarrhythmic agents have a lot of potential, but a long way to go: reduced effectiveness and dangers of reversed use-dependence, Circulation 81 (1990) 686-690.
53. A.L. Waldo, A.J. Camm, H. deRuyter, P.L. Friedman, D.J. Mac-Neil, J.F. Pauls, B. Pitt, C.M. Pratt, P.J. Schwartz, E.P. Veltri, Effect Of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral D-sotalol, Lancet 348 (1996) 7-12.
54. C. Torp-Pedersen, M. Moller, P.E. Bloch-Thomsen, L. Kober, E. Sandoe, K. Egstrup, E. Agner, J. Carlsen, J. Videbaek, B. Marchant, A.J. Camm, Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish investigations of arrhythmia and mortality on Dofetilide study group, N. Engl. J. Med. 341 (1999) 857-865.
55. + channel structure-activity relationships and mechanisms of drug-induced QT prolongation, Annu. Rev. Pharmacol. Toxicol. 43 (2003) 441-461.
56. J.S. Mitcheson, J. Chen, M. Lin, C. Culberson, M.C. Sanguinetti, A structural basis for drug-induced long QT syndrome, Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 12329-12333.
57. W. Haverkamp, W.G. Breithardt, A.J. Camm, M.J. Janse, M.R. Rosen, C. Antzelevitch, D. Escande, M. Franz, M. Malik, A. Moss, R. Shah, and the other speakers in the sessions and chairs of the workshops, The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology, Cardiovasc. Res. 47 (2000) 219-233.
58. J. Tamargo, Drug-induced torsade de pointes: from molecular biology to bedside, Jpn. J. Pharmacol. 83 (2000) 1-19.
59. F. De Ponti, E. Poluzzi, N. Montanaro, Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus, Eur. J. Clin. Pharmacol. 57 (2001) 185-209.
60. Ks potassium channel, Nature 384 (1996) 80-83.
61. Ks in guinea pig cardiac myocytes and guinea pig IsK channels by the chromanol 293B, Pflügers Arch. 432 (1996) 1094-1096.
62. Ks channels by HMR 1556, Naunyn-Schmiedebergs Arch. Pharmacol. 362 (2000) 480-488.
63. Ks in dog ventricular muscle and Purkinje fibre repolarization, J. Physiol. 523 (1) (2000) 67-81.
64. Ks by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl) -2,3-dihydro-1H-benzo[e] [1,4]diazepin-3-yl]acetamide, J. Med. Chem. 40 (1997) 3865-3868.
65. + currents, Mol. Pharmacol. 54 (1998) 220-230.
66. M.C. Sanguinetti, N.K. Jurkiewicz, A. Scott, P.K. Siegl, Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes. Mechanism of action, Circ. Res. 68 (1991) 77-84.
67. + current, on repolarization in human and guinea pig ventricular myocytes, Cardiovasc. Res. 38 (1998) 441-450.
68. Ks does not induce early afterdepolarization activity but promotes beta-adrenergic agonist-induced delayed afterdepolarization activity, J. Cardiovasc. Electrophysiol. 11 (2000) 458-465.
69. KACh in atrial fibrillation using a mouse knockout model, J. Am. Coll. Cardiol. 37 (2001) 2136-2143.
70. + channels in cardiac muscle, Nature 305 (1983) 147-148.
71. ATP channels, Physiol. Rev. 78 (1998) 227-245.
72. S.I. Koumi, R.L. Martin, A.R. Sato, Alterations in ATP-sensitive potassium channel sensitivity to ATP in failing human hearts, Am. J. Physiol. 272 (1997) H1656-H1665.
73. C.D. Wolleben, M.C. Sanguinetti, P.K. Siegl, Influence of ATP-sensitive potassium channel modulators on ischemia-induced fibrillation in isolated rat hearts, J. Mol. Cell. Cardiol. 21 (1989) 783-788.
74. ATP channels during metabolic inhibition and recovery, FASEB J. 15 (2001) 2586-2594.
75. H. Gögelein, J. Hartung, H.C. Englert, B.A. Scholkens, HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. Part I: Effects on cardiomyocytes, coronary flow and pancreatic beta-cells, J. Pharmacol. Exp. Ther. 286 (1998) 1453-1464.
76. + channels in arterial smooth muscle, Science 245 (1989) 177-180.
77. ATP channels in ischemic cardioprotection, Circulation 101 (2000) 2418-2423.
78. T.J. Colatsky, C.H. Follmer, C.F. Starmer, Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias, Circulation 82 (1990) 2235-2242.
79. H.J. Schatzmann, Herzglykoside als Hemmstoffe für den aktiven Kalium und Natriumtransport durch die Erythrozytenmembran, Helv. Physiol. Pharmacol. Acta 11 (1953) 346-354.
80. T. Akera, T.M. Brody, The role of the Na, K-ATPase in the inotropic action of digitalis, Pharmacol. Rev. 29 (1978) 187-220.
81. R.H.G. Schwinger, H. Bundgaard, J. Müller-Ehmsen, K. Kjeldsen, The Na, K-ATPase in the failing human heart, Cardiovasc. Res. 57 (2003) 913-920.
82. J. Gao, I.S. Cohen, R.T. Mathias, G.J. Baldo, The inhibitory effect of β-stimulation on the Na/K pump current in guinea pig ventricular myocytes is mediated by a cAMP-dependent PKA pathway, Pflügers Arch. 435 (1998) 479-484.
83. J. Kimura, Na-Ca exchange and Ca-sensitive non-selective cation current components of transient inward current in isolated cardiac ventricular cells of the guinea-pig, J. Physiol. 407 (1988) 79P.
84. + in single cardiac Purkinje cells, Am. J. Physiol. 256 (1989) C1086-C1092.
85. + current in cardiac cells: rectification, open probability, block and role in digitalis toxicity, Pflügers Arch. 416 (1990) 766-769.
86. The Digitalis Investigation Group, The effect of digoxin on mortality and morbidity in patients with heart failure, N. Engl. J. Med. 336 (1997) 525-533.
87. L. Perchenet, A.K. Hinde, K.C. Patel, J.C. Hancox, A.J. Levi, Stimulation of Na/Ca exchange by α-adrenergic/protein kinase A pathway in guinea-pig ventricular myocytes at 37 °C, Pflügers Arch. 439 (2000) 822-828.
88. 2+ exchange in cells expressing NCX1, J. Biol. Chem. 271 (1996) 22391-22397.
89. 2+ exchange current in guinea-pig ventricular cells, Br. J. Pharmacol. 119 (1996) 555-563.
90. 2+ exchanger, on myocardial ischemia-reperfusion injuries, Eur. J. Pharmacol. 458 (2003) 155-162.
91. 2+ overload in rat ventricular myocytes, Circulation 101 (2000) 1441-1446.
92. 2+ exchange inhibitor, does not suppress ischemia/reperfusion arrhythmias nor digitalis arrhythmias in dogs, Jpn. J. Pharmacol. 90 (2002) 229-235.
93. M. Karmazyn, The sodium-hydrogen exchange system in the heart: its role in ischemic and reperfusion injury and therapeutic implications, Can. J. Cardiol. 12 (1996) 1074-1082.
94. M. Avkiran, Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia, Am. J. Cardiol. 83 (1999) 10G-17G.
95. W. Scholz, U. Albus, I. Counillon, H. Gögelein, H.-J. Lang, W. Linz, A. Weichert, B.A. Schölkens, Protective effects of Hoe642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion, Cardiovasc. Res. 29 (1995) 260-268.
96. P. Théroux, B.R. Chaitman, N. Danchin, L. Erhardt, T. Meinertz, J.S. Schroeder, G. Tognoni, H.D. White, J.T. Willerson, A. Jessel, Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators, Circulation 102 (2000) 3032-3038.
97. + exchanger are resistant to cardiac ischemia-reperfusion injury, Circ. Res. 93 (2003) 776-782.
98. S. Nattel, Antiarrhyhthmic drug classification. A critical appraisal of their history, present status, and clinical relevance, Drugs 41 (1991) 672-701.
99. D.S. Echt, P.R. Liebson, L.B. Mitchell, R.W. Peters, D. Obias-Manno, A.H. Barker, D. Arensberg, A. Baker, L. Friedman, H.L. Greene, M.L. Huther, D.W. Richardson, and the CAST investigators, mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial, N. Eng. J. Med. 324 (1991) 781-788.
100. 2+ overload, Pharmacol. Res. 39 (1999) 167-174.